AstraZeneca/Oxford coronavirus vaccine is not effective in immune to South African variant viruses.

According to RTHK website on February 7, AstraZeneca said that the coronavirus vaccine developed in cooperation with

Oxford University seems to provide limited protection for mild symptoms caused by variant viruses found in South Africa.

Earlier, Oxford conducted research with a university in South Africa and found that the efficacy of this vaccine has significantly decreased in the face of variant viruses found in South Africa.

After the relevant research results were published in the newspaper, AstraZeneca responded.